BioMarin Secures Fast-Track Review For Hemophilia Gene Therapy In EU
Will It Be Second Time Lucky For Potential New Treatment?
BioMarin plans to file for approval of its investigational hemophilia A gene therapy in the EU in June this year but its US filing is not planned until Q2 2022. It will be the company's second attempt at success in both jurisdictions.
